摘要
Abstract
Objective: To observe the clinical short-term efficacy of cavity infusion of recombinant human endostatin (endostar) in the treatment of malignant cavity effusion, and evaluate the safety and tolerability of cavity infusion.Method: Thirty patients with more than medium malignant cavity effusion in our hospital from January 2012 to January 2015 were analyzed retrospectively. Following a maximum release all of cavity effusion, all the patients were given cavity infusion including 13 cases of cisplatin monotherapy group and 17 cases of endostar with cisplatin group. The dosage was taken as follow: endostar 30 mg per time on d1,3,5; cisplatin 40 mg each time on d1,3,5. Their short-term efficacy as well as toxicity after a treatment cycle was evaluated. Results: In the cisplatin monotherapy group, there were 0 case achieved CR, 6 cases achieved PR, 6 cases achieved SD, 1 case achieved PD, the objective response rate was 46.1%, while in the endostar with cisplatin group, there were 1 case achieved CR, 12 cases achieved PR, 2 cases achieved SD, 2 cases achieved PD, the objective response rate was 76.4%. There were significant differences between the two groups (P=0.180). Among 27 responders median TTP of cisplatin monotherapy and endostar with cisplatin group were 84 days vs 100 days (P=0.032). Drug-related toxicity of two groups was similar.Conclusion: Cavity infusion endostar combined with cispaltin can control the malignant cavity effusion better, and its clinical safety is better than cisplatin monotherapy.关键词
重组人血管内皮抑素/恶性浆膜腔积液/化学治疗Key words
Recombinant human endostatin/Malignant cavity effusion/Chemotherapy
